Medicine and Health
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
B. Besse, E. Pons-tostivint, et al.
In a groundbreaking phase 2 umbrella study, researchers, including Benjamin Besse and Patrick M. Forde, have explored innovative combination regimens for advanced non-small cell lung cancer (NSCLC) after failed immunotherapy. The combination of durvalumab with ceralasertib demonstrated remarkable efficacy, with an objective response rate of 13.9% and a median overall survival of 17.4 months. This study unveils promising directions for future investigations into NSCLC treatments.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.
